Friday, November 13, 2026

EUR/CHF Over 1% Down In The Last 10 Sessions

EUR/CHF Over 1% Down In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.17% for the last 10 sessions. At 19:07 EST on Tuesday, 11 July, EUR/CHF (EURCHF) is $0.97.

EUR/CHF's yearly highs and lows, it's 2.63% up from its 52-week low and 4.16% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.05%, a positive 0.01%, and a positive 0.20%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.05% (last week), 0.15% (last month), and 0.20% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy technical analysis: new break of the bullish trend - 10 July 2023. According to DailyForex on Monday, 10 July, "In the near term, and according to the performance on the hourly chart, it appears that the USD/JPY currency pair is trading within a sharp descending channel formation. ", "On the long run, and according to the performance on the daily chart, it appears that the USD/JPY is trading within the formation of an ascending channel. "
  • Usd/jpy rebounds from monthly low, climbs to mid-142.00s amid reviving USD demand. According to FXStreet on Monday, 10 July, "The US Dollar (USD) kicks off the new week on a positive note and for now, seems to have snapped a two-day losing streak to its lowest level since June 2022 touched on Friday, which, in turn, is seen lending some support to the USD/JPY pair. ", "Any positive surprise, however, might prompt aggressive short-covering around the USD and suggest that the USD/JPY pair's recent corrective decline from the YTD top has run its course. "
  • According to DailyForex on Monday, 10 July, "Some days agothe USD/JPY currency pairmade a new 7-month high above ¥145, but it is now trading well below that level."
  • Usd/jpy rebounds from monthly low, climbs to mid-142.00s amid reviving USD demand. According to FXStreet on Monday, 10 July, "The US Dollar (USD) kicks off the new week on a positive note and for now, seems to have snapped a two-day losing streak to its lowest level since June 2022 touched on Friday, which, in turn, is seen lending some support to the USD/JPY pair. ", "Apart from this, speculations that Japan might intervene in currency markets to prop up the Japanese Yen might further contribute to capping the upside for the USD/JPY pair and warrant caution before positioning for any further appreciating move."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com